| Autor: |
Seyed Amin Mirsadeghi, Seyed Saeed Tamehri Zadeh, Alimohammad Fakhr Yasseri, Ali Tabibi, Mohammad Hadi Radfar, Diana Taheri |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Translational Research in Urology, Vol 3, Iss 1, Pp 23-31 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2717-042X |
| DOI: |
10.22034/TRU.2021.256708.1042 |
| Popis: |
Introduction To compare the effectiveness of tamsulosin and Tolterodine in reducing stent-related symptoms with each other and with the control group we performed this randomized clinical trial. Methods 150 patients after successful first-time transurethral lithotripsy (TUL) for unilateral ureteral stones were elected for the study 17 patients were excluded in the first allocation. Other patients were randomized (With balanced blocked randomization) into three groups. In group 1, 41 patients received Tamsulosin (Omnic) 0.4mg once a day for a month and in group 2, 42 patients received tolterodine (Detrusitol) 2mg once a day for a month. In group 3, which was our control group, 50 patients received a placebo once a day for a month. Clinical stent-related symptoms questionnaires at the first visit (day 10) and before removing themes stent were completed. Two urine tests and an x-ray of the abdomen in the first visit have been performed. Results Despite the remarkable decrease in the severity of stent-related symptoms other than urine urgency in the control group (p-value0.05). Conclusion The results of our study show that administration of tolterodine and tamsulosin to reduce stent-related symptoms do not have superiority to each other and the control group. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
